Introduction
Eclampsia complicates 1 in 2000 pregnancies and accounts for a significant percentage of fetal/maternal morbidity and mortality. [1] [2] [3] Traditional management includes maternal stabilization of seizures and blood pressure, followed by delivery of the pregnancy, irrespective of gestational age. [1] [2] [3] Evidence suggests that antenatal steroids have a significant impact on perinatal morbidity and mortality, particularly impacting the respiratory and central nervous systems. 4 If pregnancy latency from diagnosis of eclampsia to delivery could be extended safely for both the fetus and the mother, improvement in perinatal outcomes may be achieved similar to improved maternal outcomes observed with the conservative management of severe pre-eclampsia. [5] [6] [7] [8] We report a compassionate off-label use of digoxin-fragmented antibody on a repeated-dose, fixed schedule in a preterm pregnancy complicated by eclampsia.
Case
A 16-year-old 70 kg primagravida at 29 weeks 5/7 days presented with a presumed diagnosis of eclampsia. Her prenatal course had been uncomplicated until the day of admission. Her past medical history was negative for chronic illness. The patient had complaints of scotomata, persistent headache and two episodes of witnessed seizure activity before presentation. A subsequent seizure occurred while she was being triaged. Initial clinical evaluation revealed a patient with postictal behavior. Her blood pressure was elevated at 160/110 mm Hg initially, whereas other vital signs were stable. Funduscopic examination revealed A-V nicking, whereas physical findings included 4 þ edema of the lower extremities and obvious facial and upper extremity edema. Deep tendon reflexes were 3 þ with two beats of clonus. Urinalysis demonstrated 2 þ proteinuria and a urine specific gravity of 1.025. Serum chemistry showed hyperuricacidemia at 8.2 mg per 100 ml, elevated creatinine of 1.0 mg per 100 ml, blood urea nitrogen of 6 mg per 100 ml, and otherwise normal electrolytes and liver enzymes. The platelet count was 429 000, with a normal white count of 10.4 and a hemoglobin/ hematocrit of 12.0 g per 100 ml, 35.6%. Serum ammonia level was 3 mmol per liter and coagulation studies were normal. Urine drug screen was negative. Computerized tomography scanning of the maternal head revealed no pathological abnormalities.
Ultrasound examination of the fetus demonstrated a singleton with a breech presentation. The estimated gestational age was consistent with the previously determined age of 29 weeks, with an estimated fetal weight of 1331 g (75%). No fetal anatomical abnormalities were noted on examination. The amniotic fluid index was 5.42 cm with fetal breathing, movement and tone noted to be present for a total biophysical profile sum of 8/10. Pretherapy Doppler flow studies of the umbilical artery demonstrated an elevated systolic-to-diastolic (S/D) ratio of 4.8 (>95%) and a resistance index of 0.79 ( Figure 1 ). Fetal cardiotocograph revealed a baseline of 135 with minimal beat-to-beat variability. Occasional non-repetitive decelerations were noted with reassuring recovery.
The patient was transported to the obstetrical intensive care unit and magnesium sulfate was started (6 g loading dose, 2 g per h maintenance). Intravenously administered fluids including magnesium sulfate were restricted to 125 cc per h. A central venous catheter, arterial line and foley urinary catheter were placed per intensive care unit protocol. The patient's family was offered compassionate off-label use of a fragmented antibody to digoxin in addition to corticosteroid administration for fetal benefit, and consent was obtained.
Dosing of fragmented antibody to digoxin was based on a treatment regimen of two antepartum patients who received the drug for eclampsia and severe pre-eclampsia.
9,10 Based upon recommended dosing for known digitalis toxicity, we used the formula of 4.0 ng per ml Â patient's body weight in kg divided by 100. Unlike the earlier patients who received either a repeated bolus or a continuous infusion, we administered the fragmented antibody on a scheduled basis every 6 h (342 mg per 6 h). After the first 6 h of therapy, the drug dose was doubled (684 mg per 6 h) secondary to persistent hypertension. The drug was continued at this level for a total of three doses and then decreased to the original level secondary to drug availability issues. This case represents the first time the fragmented antibody was administered on a repeated fixed schedule.
Blood pressure readings of 148 to 162 mm Hg systolic and 104 to 111 mm Hg diastolic were noted after the initial infusion of fragmented antibody to digoxin. Serial blood pressure measurements during the 36-h period following the doubling of the dose resulted in a mean systolic pressure of 140 mm Hg and a mean diastolic pressure of 90 mm Hg ( Table 1) . Resolution of facial and upper extremity edema was noticed along with a decrease in lower extremity edema to 1 þ . Deep tendon reflexes also improved with no clonus.
Urine output from admission to initial infusion of fragmented antibody was 300 cc over 6 h. Six hours after initial drug delivery, the average urinary output improved to 100 cc per h. Further diuresis of 5840 cc over 36 h (162 cc per h) occurred after the doubled dose started at 6 h ( Table 1 ). The urine qualitative examination revealed negative proteinuria with a specific gravity of 1.011. Creatinine decreased from 1.0 to 0.7, with the remainder of electrolytes remaining normal.
No changes in fetal cardiotocography were witnessed. Biophysical testing every 6 h was reassuring (8/10). Mid-segment umbilical artery Doppler waveforms every 6 h revealed a decreasing S/D ratio. At 20 h after the first infusion, value of S/D ratio was 2.87 (41 percentile) and resistance index was 0.65 (Figure 2) .
At hour number 36, digoxin-fragmented antibody supply was exhausted and a change back to single strength dosing was made for the final two doses. Cesarean delivery was performed 48 h following initial administration of corticosteroids secondary to a The neonate did not require any initial oxygen support and was admitted to the neonatal intensive care unit secondary to prematurity. Postoperatively, magnesium sulfate was continued for 24 h and oral antihypertensive therapy was initiated. The patient was discharged home on postoperative day no. 4, with stable blood pressures controlled with oral b-blockers. Follow-up laboratory values remained within normal limits. The neonate had no adverse sequelae and was discharged home on the thirty-first day of life. Pediatric follow-up at 2 years of age places the child at age appropriate milestones.
Discussion
This case report is the first highlighting the potential therapeutic role of repeated interval administration of fragmented antibody directed to digoxin in the treatment of antepartum eclampsia. Endogenous digitalis-like factors have been reported in the literature as a causative agent in the development of preeclampsia. [11] [12] [13] [14] [15] [16] Although the mechanism of action of the digoxinfragmented antibody is not completely clear it is believed to work by releasing the inhibition of endogenous sodium pumps that have been associated with hypertension in pregnancy. 17, 18 Two separate case reports attest to a possible clinical improvement with patients treated with the digoxin-fragmented antibody. 9, 10 The first report by Goodlin 9 in a patient with eclampsia was performed using two intravenous bolus doses given based on the patient's clinical findings until improvement in the patient's clinical symptoms. Adair et al. 10 used a continuous intravenous infusion of the same antibody and achieved similar favorable maternal outcomes in a patient with severe pre-eclampsia. The current case is unique in that digoxin-fragmented antibody was administered by intravenous bolus administration at a repeated scheduled interval of 6 h as compared with continuous infusion or a single intravenous bolus.
Current clinical observations of this patient and her very low birth weight neonate suggest the need for further research in the use of fragmented digoxin antibody in select cases of preterm preeclamptic hypertensive complications as alternative to our current management strategy. Current clinical studies such as the Digibind Efficacy Evaluation in Preeclampsia Trial (www.clinicaltrials.gov 11724) may attest to the utility of antibody-based treatment against such pregnancy-related hypertensive complications of pregnancy. Digoxin-fragmented antibody in preterm eclampsia
